Scholarlink

Study design <p>Animal study.</p> Objectives <p>To determine whether eliminating cis pT231-tau with a specific monoclonal antibody can restore neuronal structure and function after spinal cord injury (SCI).</p> Setting <p>Royan Institute, Tehran, Iran.</p> Methods <p>Adult Wistar rats underwent SCI induction using the NYU impactor device. Animals received treatment with cis pT231-tau monoclonal antibody or placebo. Outcomes were assessed via immunostaining, immunoblotting, and the Basso, Beattie, and Bresnahan (BBB) behavioral test to evaluate motor function recovery.</p> Results <p>Treatment with cis pT231-tau monoclonal antibody reduced inflammatory markers, enhanced myelin sheath formation, increased NF200 protein expression, and decreased GFAP levels compared with placebo. Behavioral testing indicated improved motor function in treated animals.</p> Conclusions <p>Eliminating cis pT231-tau using a specific monoclonal antibody mitigates neuronal damage and promotes structural and functional recovery following SCI, highlighting its therapeutic potential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Passive immunotherapy targeting pathogenic tau restores neuronal structure and function following spinal cord injury

  • 期刊论文

  • 发表日期：

    2026年4月1日

查看全文
  • Amirreza Vahedi,
  • Golnoosh Rahimi,
  • Mohadeseh Rahbar,
  • Yalda Adibi Motlagh,
  • Pegah Siahmansouri,
  • Farzaneh Sorouri,
  • Farzaneh Esmaily,
  • Seyed Massood Nabavi,
  • Sahar Kiani,
  • Koorosh Shahpasand

摘要

Study design

Animal study.

Objectives

To determine whether eliminating cis pT231-tau with a specific monoclonal antibody can restore neuronal structure and function after spinal cord injury (SCI).

Setting

Royan Institute, Tehran, Iran.

Methods

Adult Wistar rats underwent SCI induction using the NYU impactor device. Animals received treatment with cis pT231-tau monoclonal antibody or placebo. Outcomes were assessed via immunostaining, immunoblotting, and the Basso, Beattie, and Bresnahan (BBB) behavioral test to evaluate motor function recovery.

Results

Treatment with cis pT231-tau monoclonal antibody reduced inflammatory markers, enhanced myelin sheath formation, increased NF200 protein expression, and decreased GFAP levels compared with placebo. Behavioral testing indicated improved motor function in treated animals.

Conclusions

Eliminating cis pT231-tau using a specific monoclonal antibody mitigates neuronal damage and promotes structural and functional recovery following SCI, highlighting its therapeutic potential.